English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 31 May 2024, 16:00 HKT/SGT
Share:
    

Source: Avance Clinical
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical

WAKE FOREST, N.C. | ADELAIDE, AUS, MAY 31, 2024 - (ACN Newswire) - Avance Clinical, the award-winning Australian and North American CRO for biotechs, has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS, cardiometabolic, and rare diseases specialist CRO with extensive site relationships across Europe. The non-exclusive MOU between the two offers a streamlined global solution for both their biotech clients.

Avance Clinical CEO Yvonne Lungershausen said “Julius Clinical are an ideal partner for Avance Clinical because they lead with scientific expertise and can support our biotech clients with specialist CNS, cardiometabolic and rare diseases clinical operations and site relationships in Europe. Julius Clinical clients can also leverage Avance Clinical operations in Asia, Australia, New Zealand and North America for their expanded later phase trials”.

Martijn Wallert, CEO of Julius Clinical, added, “We are excited to be partnering with Avance Clinical. Biotechs seek partners that can start quickly with high-quality data accepted by regulatory agencies like the MHRA, EMA, and US FDA. Together with Avance Clinical, we offer a nimble, flexible, and scientifically robust service, providing a tailored global solution”. Julius Clinical has supported over 380 clinical trials, enrolling some 220,000 participants in around 39 countries.

Avance Clinical is committed to accelerating drug development for biotech clients from early to later phase trials, with study data accepted by regulatory authorities including the EMA and FDA, allowing clients to remain with one CRO throughout their clinical development program. “This is our GlobalReady program, currently utilized by more than 90 biotech clients. Our globalized strategy ensures efficiency at every step,” Lungershausen said.

“In addition to our existing operations, our specialist partner CROs work alongside our teams to ensure our biotech clients benefit from the most experienced scientific, regulatory, and clinical operations teams across various therapeutic areas and regions.  Avance Clinical is now a global CRO for biotechs."

Meet Avance Clinical at BIO 2024Book a meeting.

About Avance Clinical

Avance Clinical is the largest premium full-service Australian and North American CRO delivering quality clinical trials with globally accepted data, in Australia, New Zealand and the US. The company's clients are completing Phase I to Phase III of drug development programs which require fast, agile, and adaptive solution-oriented clinical research services. Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than 26 years.

Avance Clinical offers pre-clinical services with their experienced ClinicReady team from pre-clinical through to Phase III clinical services, leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review. Avance Clinical uses state-of-the-art technology and systems across all functional areas. Tech partners include Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio. Learn more at www.avancecro.com.

About Julius Clinical

Julius Clinical, founded in 2008 and based in Zeist, The Netherlands, is a scientifically focused CRO providing end-to-end clinical trial service to pharmaceutical and biotechnology customers, as well as governments and academia. Julius Clinical’s renowned scientific leaders are at the forefront of their fields, which combine with operational excellence and a global network of research sites to deliver tailor-made solution for customers and their clinical trials. With a focus on the therapeutic areas of CNS, cardio-metabolic, renal, and rare diseases, Julius Clinical has grown to approximately 200 employees and has supported over 380 clinical trials, enrolling more than 220,000 participants in around 39 countries. Visit www.juliusclinical.com.

Contact:
Kate Thompson,
Avance Clinical
media@avancecro.com



Topic: Press release summary
Source: Avance Clinical

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Avance Clinical Related News
July 24, 2024 08:00 HKT/SGT
Avance Clinical 任命亞洲區域總監,作為全球擴展計畫的一部分
July 24, 2024 08:00 HKT/SGT
Avance Clinical 任命亚洲区域总监,作为全球扩展计划的一部分
July 24, 2024 08:00 HKT/SGT
Avance Clinical, 글로벌 확장 프로그램의 일환으로 아시아 지역 이사 임명
July 23, 2024 16:00 HKT/SGT
Avance Clinical Appoints Asia Regional Director as Part of Global Expansion Program
June 4, 2024 22:56 HKT/SGT
BIO24에서 발표된 새로운 연구에서 내부 규제 사항을 갖춘 CRO는 생명공학 기업에게 30%의 절감을 제공하고, 시간을 절반으로 줄이며, 위험을 줄입니다
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575